Abilify in Bipolar Disorder for 6 Weeks Treatment Effectiveness

Phase 4

Completed

• Conditions: Bipolar Disorder

• Registration Number: NCT00545142
• Lead Sponsor: Korea Otsuka Pharmaceutical Co., Ltd.

Brief Summary

To demonstrate the efficacy and safety of co-administration of Abilify(aripiprazole) with Depakote(divalproate) in the acute phase of 6-week treatment of acute mania in patients with bipolar disorder.

Detailed Description

Further study details as provided by Korea OIAA

Study Timeline

• Study Start: 2007-10
• Study First Submitted: 2007-10-16
• Study First Submitted QC: 2007-10-16
• Study First Posted: 2007-10-17
• Status Verified: 2010-06
• Primary Completion: 2010-06
• Study Completion: 2010-06
• Last Update Submitted: 2010-06-24
• Last Update Posted: 2010-06-25

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: 280

Inclusion Criteria

Inclusion Criteria:

1. Mania or mixed episode of Bipolar disorder Bipolar disorder, mania or mixed episode according to DSM-IV
2. The periods of mania or mixed episode should be within 3 months, and YMRS score at enrollment be more than 20.
3. Male and female between the age of 18 and 65 (In case of child-bearing women, negative pregnancy test results should be confirmed before the administration of the investigational drug and appropriate contraception be used. Pregnant and breast-feeding women cannot be included)
4. Patients who can consent to participate in this clinical trial
5. Patients who understand this trial and comply with all protocol requirements

Exclusion Criteria

1. Patients with the following clinical symptoms diagnosed using DSM-IV:

   • Delirium, dementia, amnestic or other cognitive disorders
   • Schizophrenia or schizoaffective disorder

2. Patients who do not respond to clozapine

3. Patients who are expected to require the administration of prohibited concomitant drugs during the clinical trial period

4. Patients diagnosed with substance-related disorder according to DSM-IV within the past 3 months (abuse, intoxication, dependency and/or withdrawal symptoms). The abuse of benzodiazepines is included with the exception of caffeine or nicotine.

5. Patients known to have allergy or hypersensitivity reaction to Ablify(aripiprazole) or other quinolinones

6. Patients at high risk of suicide attempt or with the history of murder or mental status test

7. Patients with the history of neuroleptic malignant syndrome

8. Patients with the past history which may cause serious adverse events that can affect the safety or efficacy evaluation during the clinical trial period

9. Patients with vital sign or ECG results in the clinically significant abnormal laboratory test Patients with clinically significantly abnormal laboratory results, vital sign or ECG results

10. Pregnant women or child-bearing women who do not or cannot use appropriate contraception

11. Patients given psychotropic medications (except benzodiazepines) one day before baseline visit

12. Patients treated with Fluoxetine for the last 4 weeks

13. Patients who participated in clinical trials with other investigational drugs for the last one month

14. Patients with the history of convulsive disorder

15. Patients with the history of more than 4 mood episodes each year (rapid cycling) during the last 2 years prior to screening.

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: SINGLE_GROUP

Primary Outcome Measures

Name	Time	Method
Changes in the YMRS total score from baseline to the end of 6-week study	Throughout the study

Secondary Outcome Measures

Name	Time	Method
Changes in YMRS total scores from baseline to the end of 6-week study	Throughout the study

Trial Locations

Locations (1)

St. Mary's hospital; 🇰🇷 Seoul, Korea, Republic of